Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Myriad Genetics (MYGN) Reports In-Line Q2 EPS, Revenues Beat
February 23, 2021 4:29 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $154.6 million versus the consensus estimate of $150.39 million.
Highlights:
Revenue of $154.6 million up 6% sequentially in quarter ended Dec. 31, 2020GAAP Earnings per share (EPS) of ($0.59) and adjusted EPS of ($0.12)Despite COVID-19 headwinds, total test volumes increase 7% sequentially with stable pricingSigned in-network agreement with the majority of Anthem Blue Cross Blue Shield health plans, the second... More